Wells Fargo & Company Issues Positive Forecast for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target lifted by Wells Fargo & Company from $376.00 to $377.00 in a report issued on Friday,Benzinga reports. The brokerage currently has an “equal weight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s target price indicates a potential upside of 24.67% from the stock’s previous close.

Several other equities analysts have also weighed in on ALNY. Royal Bank Of Canada reduced their price target on shares of Alnylam Pharmaceuticals from $500.00 to $465.00 and set an “outperform” rating for the company in a research report on Tuesday, January 20th. Morgan Stanley cut their target price on shares of Alnylam Pharmaceuticals from $495.00 to $408.00 and set an “equal weight” rating for the company in a research report on Friday, January 30th. HC Wainwright reiterated a “buy” rating and set a $510.00 target price on shares of Alnylam Pharmaceuticals in a research report on Wednesday, March 25th. Weiss Ratings lowered shares of Alnylam Pharmaceuticals from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, April 6th. Finally, Oppenheimer began coverage on shares of Alnylam Pharmaceuticals in a research report on Wednesday, January 7th. They set an “outperform” rating and a $500.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $472.83.

Alnylam Pharmaceuticals Stock Performance

ALNY traded down $7.10 during trading on Friday, hitting $302.39. 68,548 shares of the company traded hands, compared to its average volume of 1,305,320. The firm has a market cap of $40.35 billion, a P/E ratio of 177.33 and a beta of 0.39. The stock’s fifty day moving average is $320.11 and its 200 day moving average is $377.45. The company has a quick ratio of 2.71, a current ratio of 2.76 and a debt-to-equity ratio of 1.28. Alnylam Pharmaceuticals has a one year low of $245.96 and a one year high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share for the quarter, beating the consensus estimate of $0.90 by $1.09. The company had revenue of $1.17 billion during the quarter, compared to analyst estimates of $1.12 billion. Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The firm’s revenue for the quarter was up 96.4% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.44) earnings per share. As a group, equities analysts predict that Alnylam Pharmaceuticals will post 6.75 EPS for the current fiscal year.

Insider Activity

In other news, CEO Yvonne Greenstreet sold 6,958 shares of the stock in a transaction dated Friday, February 13th. The shares were sold at an average price of $310.08, for a total value of $2,157,536.64. Following the sale, the chief executive officer directly owned 85,662 shares of the company’s stock, valued at approximately $26,562,072.96. This represents a 7.51% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Melissa Mclaughlin sold 2,286 shares of the stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $330.42, for a total transaction of $755,340.12. Following the completion of the sale, the insider directly owned 9,443 shares in the company, valued at approximately $3,120,156.06. The trade was a 19.49% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 38,656 shares of company stock valued at $12,370,696. 0.86% of the stock is currently owned by corporate insiders.

Institutional Trading of Alnylam Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the company. Sequoia Financial Advisors LLC lifted its stake in Alnylam Pharmaceuticals by 8.3% in the 1st quarter. Sequoia Financial Advisors LLC now owns 4,560 shares of the biopharmaceutical company’s stock worth $1,509,000 after purchasing an additional 348 shares in the last quarter. Resona Asset Management Co. Ltd. lifted its stake in Alnylam Pharmaceuticals by 1.5% in the 1st quarter. Resona Asset Management Co. Ltd. now owns 39,832 shares of the biopharmaceutical company’s stock worth $13,085,000 after purchasing an additional 585 shares in the last quarter. Swedbank AB lifted its stake in Alnylam Pharmaceuticals by 0.4% in the 1st quarter. Swedbank AB now owns 62,215 shares of the biopharmaceutical company’s stock worth $20,585,000 after purchasing an additional 273 shares in the last quarter. Whittier Trust Co. of Nevada Inc. lifted its stake in Alnylam Pharmaceuticals by 167.1% in the 1st quarter. Whittier Trust Co. of Nevada Inc. now owns 219 shares of the biopharmaceutical company’s stock worth $72,000 after purchasing an additional 137 shares in the last quarter. Finally, Ascentis Independent Advisors purchased a new stake in Alnylam Pharmaceuticals in the 1st quarter worth approximately $64,000. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals News Summary

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Q1 beat — Alnylam reported Q1 revenue of $1.17 billion and EPS of $1.99, topping analyst estimates and showing ~96% revenue growth year-over-year; the results underpin the bullish case on product uptake and margin improvement. Alnylam Q1 earnings press release & transcript
• Positive Sentiment: Analyst support — Brokers maintain a positive stance (consensus ~“Moderate Buy”) and H.C. Wainwright reiterated a Buy, which can support investor confidence after the beat. Consensus recommendation article H.C. Wainwright note
• Neutral Sentiment: FY?2026 revenue outlook roughly in line — the company issued FY?2026 revenue guidance in the ~$5.3B–$5.8B range (around consensus), which moderates upside surprise potential; EPS guidance detail was less clear in published notes. Slide deck / guidance details
• Neutral Sentiment: Earnings call commentary — the full call transcript provides management color on growth drivers and pipeline cadence; useful for investors assessing sustainability of the beat. Earnings call transcript
• Negative Sentiment: Outside review raises downside risk — an external review highlighted that ALNY carries a high risk of significant losses, a regulatory/structural concern that can amplify volatility and prompt cautious positioning by institutional holders. Outside review warning

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.